The pathogenesis and pathology of COPD: Identifying risk factors and improving morbidity and mortality

Advanced Studies in Medicine

Volumn 4, Issue 10 A, 2004, Pages

  Scanlon, Paul D ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; TOBACCO SMOKE; TOXIC SUBSTANCE;

ASTHMA; BRONCHODILATATION; CHRONIC BRONCHITIS; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DISEASE PREDISPOSITION; EMPHYSEMA; ENVIRONMENTAL EXPOSURE; GENETIC PREDISPOSITION; HUMAN; MORBIDITY; MORTALITY; OXYGEN THERAPY; PATHOGENESIS; PATHOLOGY; PATIENT COMPLIANCE; QUALITY OF LIFE; RESPIRATORY TRACT INFLAMMATION; REVIEW; RISK FACTOR; SMOKING AND SMOKING RELATED PHENOMENA; SMOKING CESSATION; SURGERY; SURVIVAL;

EID: 11144265771     PISSN: 15303004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (6)

1. GOLD. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Workshop Report, updated 2003. Available at: www.gold-copd.com. Accessed June 14, 2004.
2. Molfino NA. Genetics of COPD. Chest. 2004;125(5):1929-1940.
3. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med. 2000;343(4):269-280.
4. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ. 1977;1(6077):1645-1648.
5. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med. 2002;166(5):675-679.
6. Anthonisen NR, et al. Lung Health Study mortality paper, submitted to Annals of Internal Medicine, June 2004.